With the advantages of simultaneous screening rare or even unknown ALK fusion patterns as well as somatic mutations, NGS-based ctDNA assay might not only provide a more comprehensive landscape of advanced ALK-positive NSCLC, but also offer more opportunities of ALK inhibitors to this subset of patients. This evidence concerns the gene ALK and non-small cell lung carcinoma.